Eliem Therapeutics (ELYM) News Today → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free ELYM Stock Alerts $7.66 -0.01 (-0.13%) (As of 05/30/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 2:10 AM | americanbankingnews.comEliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest UpdateMay 29 at 4:30 AM | marketbeat.comShort Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Rises By 127.2%Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 128,800 shares, a growth of 127.2% from the April 30th total of 56,700 shares. Based on an average trading volume of 850,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.7% of the shares of the company are sold short.May 23, 2024 | americanbankingnews.comEliem Therapeutics (NASDAQ:ELYM) Trading 0.4% Higher May 17, 2024 | benzinga.comEliem Therapeutics Stock (NASDAQ:ELYM), Earnings Estimates, EPS, and RevenueApril 25, 2024 | marketbeat.comShort Interest in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Increases By 4,453.8%Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Currently, 3.3% of the company's stock are short sold. Based on an average trading volume of 665,800 shares, the short-interest ratio is currently 0.9 days.April 24, 2024 | marketbeat.comBML Capital Management LLC Boosts Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)BML Capital Management LLC boosted its position in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 12.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,180,000 shares of the compApril 23, 2024 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Trading 0.5% Higher Eliem Therapeutics (NASDAQ:ELYM) Shares Up 0.5%April 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmApril 12, 2024 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 11, 2024 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, ELYM, MODNApril 11, 2024 | finance.yahoo.comEliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines DealApril 11, 2024 | msn.comEnlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare moversApril 11, 2024 | markets.businessinsider.comEliem Therapeutics To Buy Tenet Medicines, Plans $120 Mln Private Placement; Stock Up In Pre-marketApril 11, 2024 | businesswire.comELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to ShareholdersApril 11, 2024 | globenewswire.comEliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementApril 5, 2024 | msn.comELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023March 6, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn SituationFebruary 18, 2024 | marketbeat.comSilverarc Capital Management LLC Lowers Holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM)Silverarc Capital Management LLC trimmed its holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) by 75.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,110 shares of the company's stock after sellingFebruary 3, 2024 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Shares Up 3.5%Eliem Therapeutics (NASDAQ:ELYM) Trading Up 3.5%November 19, 2023 | morningstar.comCheckpoint Therapeutics Inc CKPTNovember 15, 2023 | morningstar.comEliem Therapeutics Inc ELYMSeptember 28, 2023 | finance.yahoo.comEliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJuly 21, 2023 | finance.yahoo.comEliem (ELYM) to Explore Strategic Options, Stock Rises 6%July 21, 2023 | msn.comEliem Therapeutics’ stock soars 21% premarket after company says it may sell itselfJuly 20, 2023 | benzinga.comWhat's Happening With Eliem Therapeutics Shares Today?July 20, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic AlternativesJuly 20, 2023 | marketwatch.comEliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYMJuly 20, 2023 | markets.businessinsider.comWhy Is Eliem Therapeutics (ELYM) Stock Up 6% Today?July 20, 2023 | finance.yahoo.comEliem Therapeutics Announces Plans to Explore Strategic AlternativesJune 7, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)May 25, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)May 12, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business HighlightsMay 11, 2023 | seekingalpha.comEliem Therapeutics GAAP EPS of -$0.84May 11, 2023 | finance.yahoo.comEliem Therapeutics Reports First Quarter Financial Results and Business HighlightsMay 5, 2023 | marketbeat.comTrading was temporarily halted for "ELYM" at 10:05 AM with a stated reason of "LULD pause."April 21, 2023 | finance.yahoo.comWe're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash WiselyMarch 9, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)March 7, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsMarch 6, 2023 | finance.yahoo.comEliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsFebruary 23, 2023 | seekingalpha.comELYM Eliem Therapeutics, Inc.February 23, 2023 | finance.yahoo.comEliem Therapeutics slashing staff amid leadership shakeupFebruary 18, 2023 | finance.yahoo.comEliem Pauses Development On Depression Drug, Lays Off 55% WorkforceFebruary 10, 2023 | msn.comEliem Therapeutics down after announcing reprioritization plans, layoffsFebruary 9, 2023 | finance.yahoo.comEliem Therapeutics Provides Strategic Update and Announces Leadership TransitionFebruary 9, 2023 | marketbeat.comTrading was temporarily halted for "ELYM" at 04:02 PM with a stated reason of "News pending."February 6, 2023 | marketbeat.comTrading was temporarily halted for "ELYM" at 09:02 AM with a stated reason of "LULD pause." Trading set to resume at 09:02 AM. November 30, 2022 | finance.yahoo.comEliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual ConferenceNovember 14, 2022 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Third Quarter Financial and Business HighlightsNovember 12, 2022 | finance.yahoo.comIs Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth?November 8, 2022 | finance.yahoo.comEliem Therapeutics to Participate at Two Upcoming Investor Conferences Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Are You Positioned For The New Energy Goldrush? (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. ELYM Media Mentions By Week ELYM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELYM News Sentiment▼0.940.82▲Average Medical News Sentiment ELYM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELYM Articles This Week▼50▲ELYM Articles Average Week Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Generation Bio News 2seventy bio News Prelude Therapeutics News Design Therapeutics News Aldeyra Therapeutics News Ovid Therapeutics News G1 Therapeutics News Akebia Therapeutics News Werewolf Therapeutics News Conduit Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELYM) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarElon Musk’s Final Masterpiece: “X-9840”Paradigm PressBiden Nomination CANCELED?The Freeport SocietyGold Set to EXPLODE!Gold Safe ExchangeUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
